GDC-0980-induced apoptosis is enhanced by autophagy inhibition in human pancreatic cancer cells

Biochemical and Biophysical Research Communications

Volumn 453, Issue 3, 2014, Pages 533-538

  Tang, Jian Ying ^a   Dai, Tu ^b   Zhang, Hui ^a   Xiong, Wu Jun ^a   Xu, Ming Zheng ^a   Wang, Xu Jing ^a   Tang, Qing He ^a   Chen, Bo ^a   Xu, Ming ^a  

^a Tongji University   (China)

^b WUXI NO 2 PEOPLE S HOSPITAL   (China)

Author keywords

Autophagy and chemo sensitization; GDC 0980; Pancreatic cancer; PI3K AKT mTOR

Indexed keywords

3 METHYLADENINE; AMMONIUM CHLORIDE; APITOLISIB; BAFILOMYCIN A1; BECLIN 1; CASPASE INHIBITOR; HYDROXYCHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P62; SMALL INTERFERING RNA; 1-(4-((2-(2-AMINOPYRIMIDIN-5-YL)-7-METHYL-4-MORPHOLINOTHIENO(3,2-D)PYRIMIDIN-6-YL)METHYL)PIPERAZIN-1-YL)-2-HYDROXYPROPAN-1-ONE; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; MAP1LC3B PROTEIN, HUMAN; MEMBRANE PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSOL; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT CHAIN; PANCREAS CANCER; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; UPREGULATION; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

MAMMALIA;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; PANCREATIC NEOPLASMS; PYRIMIDINES;

EID: 84918510934     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.09.115     Document Type: Article

References (39)

1. E. Costello, J.P. Neoptolemos, Pancreatic cancer in 2010, new insights for early intervention and detection, Nat. Rev. Gastroenterol. Hepatol. 8 (2011) 71-73.
2. M. Ducreux, V. Boige, D. Malka, Treatment of advanced pancreatic cancer, Semin. Oncol. 34 (2007) S25-S30.
3. M. Hidalgo, Pancreatic cancer, N. Engl. J. Med. 362 (2010) 1605-1617.
4. H. Min, M. Xu, Z.R. Chen, J.D. Zhou, M. Huang, K. Zheng, X.P. Zou, Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells, Cancer Chemother. Pharmacol. 74 (2014) 167-176.
5. L. Gong, B. Yang, M. Xu, B. Cheng, X. Tang, P. Zheng, Y. Jing, G.J. Wu, Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production, Cancer Chemother. Pharmacol. 73 (2014) 69-77.
6. J. Kim, Y.C. Kim, C. Fang, R.C. Russell, J.H. Kim, W. Fan, R. Liu, Q. Zhong, K.L. Guan, Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy, Cell 152 (2013) 290-303.
7. D.A. Fruman, C. Rommel, PI3K and cancer: lessons, challenges and opportunities, Nat. Rev. Drug Discov. 13 (2014) 140-156.
8. J. Rodon, R. Dienstmann, V. Serra, J. Tabernero, Development of PI3K inhibitors: lessons learned fromearly clinical trials, Nat. Rev. Clin. Oncol. 10 (2013) 143-153.
9. B. Vanhaesebroeck, L. Stephens, P. Hawkins, PI3K signalling: the path to discovery and understanding, Nat. Rev. Mol. Cell Biol. 13 (2012) 195-203.
10. V. Papadimitrakopoulou, Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer, J. Thorac. Oncol. 7 (2012) 1315-1326.
11. R. Ferro, M. Falasca, Emerging role of the KRAS-PDK1 axis in pancreatic cancer, World J. Gastroenterol. 20 (2014) 10752-10757.
12. M.A. Collins, M. Pasca di Magliano, Kras as a key oncogene and therapeutic target in pancreatic cancer, Front. Physiol. 4 (2013) 407.
13. C.M. Parsons, D. Muilenburg, T.L. Bowles, S. Virudachalam, R.J. Bold, The role of Akt activation in the response to chemotherapy in pancreatic cancer, Anticancer Res. 30 (2010) 3279-3289.
14. S.S.W. Ng, M.S. Tsao, S. Chow, D.W. Hedley, Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells, Cancer Res. 60 (2000) 5451-5455.
15. A. Agarwal, M.W. Saif, KRAS in pancreatic cancer, JOP 15 (2014) 303-305.
16. N. Bardeesy, R.A. DePinho, Pancreatic cancer biology and genetics, Nat. Rev. Cancer 2 (2002) 897-909.
17. S.M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers, C. Garcia-Echeverria, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity, Mol. Cancer Ther. 7 (2008) 1851-1863.
18. P. Liu, H. Cheng, T.M. Roberts, J.J. Zhao, Targeting the phosphoinositide 3-kinase pathway in cancer, Nat. Rev. Drug Discov. 8 (2009) 627-644.
19. J.J. Wallin, K.A. Edgar, J. Guan, M. Berry, W.W. Prior, L. Lee, J.D. Lesnick, C. Lewis, J. Nonomiya, J. Pang, L. Salphati, A.G. Olivero, D.P. Sutherlin, C. O'Brien, J.M. Spoerke, S. Patel, L. Lensun, R. Kassees, L. Ross, M.R. Lackner, D. Sampath, M. Belvin, L.S. Friedman, GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway, Mol. Cancer Ther. 10 (2011) 2426-2436.
20. P. Gao, C. Bauvy, S. Souquere, G. Tonelli, L. Liu, Y. Zhu, Z. Qiao, D. Bakula, T. Proikas-Cezanne, G. Pierron, P. Codogno, Q. Chen, M. Mehrpour, The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells, J. Biol. Chem. 285 (2010) 25570-25581.
21. M.J. Abedin, D. Wang, M.A. McDonnell, U. Lehmann, A. Kelekar, Autophagy delays apoptotic death in breast cancer cells following DNA damage, Cell Death Differ. 14 (2007) 500-510.
22. T. Kanzawa, I.M. Germano, T. Komata, H. Ito, Y. Kondo, S. Kondo, Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells, Cell Death Differ. 11 (2004) 448-457.
23. S. Paglin, T. Hollister, T. Delohery, N. Hackett, M. McMahill, E. Sphicas, D. Domingo, J. Yahalom, A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles, Cancer Res. 61 (2001) 439-444.
24. W. Bursch, A. Ellinger, H. Kienzl, L. Torok, S. Pandey, M. Sikorska, R. Walker, R.S. Hermann, Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy, Carcinogenesis 17 (1996) 1595-1607.
25. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N. Engl. J. Med. 339 (1998) 1349-1357.
26. P. Boya, R.A. Gonzalez-Polo, N. Casares, J.L. Perfettini, P. Dessen, N. Larochette, D. Metivier, D. Meley, S. Souquere, T. Yoshimori, G. Pierron, P. Codogno, G. Kroemer, Inhibition of macroautophagy triggers apoptosis, Mol. Cell. Biol. 25 (2005) 1025-1040.
27. J. Reyjal, K. Cormier, S. Turcotte, Autophagy and cell death to target cancer cells: exploiting synthetic lethality as cancer therapies, Adv. Exp. Med. Biol. 772 (2014) 167-188.
28. D.C. Rubinsztein, P. Codogno, B. Levine, Autophagy modulation as a potential therapeutic target for diverse diseases, Nat. Rev. Drug Discov. 11 (2012) 709-730.
29. Y. Li, J. Zhang, X. Chen, T. Liu, W. He, Y. Chen, X. Zeng, Molecular machinery of autophagy and its implication in cancer, Am. J. Med. Sci. 343 (2012) 155-161.
30. R.K. Amaravadi, D. Yu, J.J. Lum, T. Bui, M.A. Christophorou, G.I. Evan, A. Thomas-Tikhonenko, C.B. Thompson, Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma, J. Clin. Invest. 117 (2007) 326-336.
31. P. Codogno, A.J. Meijer, Autophagy and signaling: their role in cell survival and cell death, Cell Death Differ. 12 (Suppl. 2) (2005) 1509-1518.
32. R. Koyama-Nasu, R. Haruta, Y. Nasu-Nishimura, K. Taniue, Y. Katou, K. Shirahige, T. Todo, Y. Ino, A. Mukasa, N. Saito, M. Matsui, R. Takahashi, A. Hoshino-Okubo, H. Sugano, E. Manabe, K. Funato, T. Akiyama, The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells, Oncogene 33 (2014) 2236-2244.
33. J.A. Menendez, L. Vellon, C. Oliveras-Ferraros, S. Cufi, A. Vazquez-Martin, MTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging, Cell Cycle 10 (2011) 3658-3677.
34. R.K. Amaravadi, C.B. Thompson, The roles of therapy-induced autophagy and necrosis in cancer treatment, Clin. Cancer Res. 13 (2007) 7271-7279.
35. B. Poole, S. Ohkuma, Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages, J. Cell Biol. 90 (1981) 665-669.
36. H. Glaumann, J. Ahlberg, Comparison of different autophagic vacuoles with regard to ultrastructure, enzymatic composition, and degradation capacity - formation of crinosomes, Exp. Mol. Pathol. 47 (1987) 346-362.
37. P.O. Seglen, P.B. Gordon, 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes, Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 1889-1892.
38. A. Yart, P. Mayeux, P. Raynal, Gab1, SHP-2 and other novel regulators of Ras: targets for anticancer drug discovery?, Curr Cancer Drug Targets 3 (2003) 177-192.
39. L.L. Fu, Y. Cheng, B. Liu, Beclin-1: autophagic regulator and therapeutic target in cancer, Int. J. Biochem. Cell Biol. 45 (2013) 921-924.